PORT
WASHINGTON, N.Y., May 17, 2024
/PRNewswire/ -- Jason S. Goldstein, Senior Litigation Counsel
in the Mass Torts Department for the national law firm Parker
Waichman LLP, was appointed to the Plaintiffs' Steering Committee
("PSC") in the multi-district litigation (MDL) involving injuries
allegedly caused by GLP-1 RAS pharmaceutical drugs,
including, but not limited to, Ozempic ®, Wegovy ® and Mounjaro ®.
The Order was entered on May 8,
2024.
Mr. Goldstein brings to the group his considerable experience in
mass torts litigation along with the extensive knowledge and
experience of the Parker Waichman firm, long involved in
multi-district litigation nationwide.
Mr. Goldstein has previously been selected to serve on the
Plaintiff's Steering Committee for In Re: Exactech Polyethylene
Orthopedic Products Liability Litigation (MDL 3044), pending in
the United States District Court
for the Eastern District of New
York before the Honorable Nicholas Garaufis. Mr. Goldstein
also served as a committee member for In Re: Elmiron
(Pentosan Polysulfate Sodium) Products Liability Litigation
(MDL 2973) and a trial team member for In Re: DePuy
Orthopaedics, Inc., Pinnacle Hip Implant Products Liability
Litigation MDL 2244).
Jerrold S. Parker, founding
partner of Parker Waichman LLP, commented that "Jason has been a
fierce advocate for our clients and will vigorously fight for the
rights of the injured plaintiffs in the In Re: Glugagon-Like
Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability
Litigation along with the other members of the Plaintiffs'
Steering Committee and the Parker Waichman team."
Parker Waichman LLP currently represents hundreds of plaintiffs
who have been harmed due to prescription weight loss products, and
anticipates that the size and scope of the litigation will continue
to increase. Plaintiffs allege that the use of
Glugagon-Like Peptide-1 Receptor agonists (GLP-1 RAS) weight loss
products can cause users to sustain serious injuries including
gastroparesis, intraoperative pulmonary aspiration, and deep vein
thrombosis.
Mr. Goldstein joins a diverse group in this Plaintiffs' Steering
Committee, which is comprised of many of the most highly
accomplished men and women in the field of plaintiffs' consumer
products litigation. "It is an honor to be appointed by the Court
to this talented and diverse team in such an important litigation,"
said Mr. Goldstein.
If you or a loved one believes you have been injured as a result
of Glugagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS)
prescription weight loss products, please call our law firm at
1-800-968-7529 or visit our website at www.yourlawyer.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jason-s-goldstein-of-parker-waichman-llp-named-to-plaintiffs-steering-committee-in-national-glugagon-like-peptide-1-receptor-agonists-glp-1-ras-products-liability-litigation-302149255.html
SOURCE Parker Waichman LLP